Baj Z, Pokoca L, Majewska E, Luciak M, Tchórzewski H
Department of Pathophysiology and Immunology, Institute of Basic Medical Sciences, Lódź, Poland.
Arch Immunol Ther Exp (Warsz). 1992;40(3-4):201-6.
We investigated subpopulations of T lymphocytes, NK cell number and cytotoxic activity in 14 chronic uremic patients on regular hemodialysis treatment. We observed a significantly decreased absolute lymphocyte number and percentage of CD3 cells. Relative numbers of CD16 cells were significantly elevated, but NK cell cytotoxic activity was within a normal range. Nine patients with chronic renal anemia on maintenance hemodialysis were enrolled in rHu-EPO treatment trial. The treatment was continued till the hematocrit level reached 30%. Each of the patients had corrected anemia and well-being. After 12 weeks of the treatment we observed in these patients decreases in CD3, CD4, CD8 and CD16 cell numbers and elevation of CD4/CD8 ratio. Cytotoxic activity of NK cells did not change significantly. Presented results indicate that chronic hemodialysis patients have significantly diminished lymphocyte number. rHu EPO treatment affects the T lymphocyte subsets inducing a deep decrease of CD8 and CD16 cell percentage leading to normalisation of the CD4/CD8 ratio.
我们研究了14例接受常规血液透析治疗的慢性尿毒症患者的T淋巴细胞亚群、NK细胞数量及细胞毒性活性。我们观察到绝对淋巴细胞数量及CD3细胞百分比显著降低。CD16细胞的相对数量显著升高，但NK细胞的细胞毒性活性在正常范围内。9例维持性血液透析的慢性肾性贫血患者参加了重组人促红细胞生成素（rHu-EPO）治疗试验。治疗持续至血细胞比容水平达到30%。每位患者的贫血得到纠正且状态良好。治疗12周后，我们观察到这些患者的CD3、CD4、CD8及CD16细胞数量减少，CD4/CD8比值升高。NK细胞的细胞毒性活性无显著变化。呈现的结果表明慢性血液透析患者的淋巴细胞数量显著减少。rHu-EPO治疗影响T淋巴细胞亚群，导致CD8和CD16细胞百分比大幅下降，使CD4/CD8比值恢复正常。
